カテゴリー： 世界, 医療/バイオ, MarketsandMarkets

世界の患者腫瘍移植/PDXモデル市場（～2028年）：種類別（マウス、ラット）、移植方法別（皮下、同所）、腫瘍種類別（呼吸器、血液）、用途別（医薬品開発、バイオバンク）、エンドユーザー別（製薬、バイオテクノロジー、CRO）

【英語タイトル】Patient-Derived Xenograft / PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028

MarketsandMarketsが出版した調査資料（BT5576-23）・商品コード：BT5576-23
・発行会社（調査会社）：MarketsandMarkets
・発行日：2023年8月30日
・ページ数：237
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：バイオ
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

"患者腫瘍移植/PDXモデル市場は、予測期間中13.4％のCAGRで、2023年の366百万米ドルから2028年には687百万米ドルに達すると予測"
世界の患者由来異種移植片/ PDXモデル市場の成長を促進する主な要因は、前臨床の予測可能性の向上、個別化医療の進歩、癌の有病率の上昇です。しかし、動物モデルの使用をめぐる倫理的な懸念は、市場の成長をある程度抑制すると予想されます。
患者腫瘍移植/PDXモデル市場は、タイプ、移植方法、腫瘍タイプ、用途、エンドユーザー、地域に基づいてセグメント化されています。

"タイプ別では、マウスモデル分野が患者腫瘍移植/PDXモデル市場で最大のシェアを占める"
タイプ別では、患者腫瘍移植/PDXモデル市場はマウスモデルとラットモデルに分類されます。マウスモデルは、操作や調達が容易であること、ラットと比較して施設での観察下での飼育が必要最小限であることから、患者腫瘍移植/PDXモデル市場における製品の成長率が高いことから、2023年の市場規模はマウスモデルが最も大きく、急成長しています。

"移植方法別では、皮下移植セグメントが患者腫瘍移植/PDXモデル市場で最大のシェアを占める"
移植方法に基づき、市場は皮下移植、同所移植、その他の移植方法（異所移植、眼内移植、腎被膜下移植）に区分されます。2023年には、皮下移植が患者腫瘍移植/PDXモデル市場で最大のシェアを占め、急成長しています。皮下移植では、患者由来の腫瘍組織を宿主動物（多くの場合マウス）の皮下に移植します。この方法は、他の移植方法に比べて比較的簡単で侵襲が少ないため、研究者にとって実用的な選択肢となっています。

"北米：患者腫瘍移植/PDXモデル市場で最大のシェア"
患者腫瘍移植/PDXモデル市場で最大のシェアを占めたのは北米です。この地域は、高度に発達した強固なバイオ医薬品産業を有し、高度な研究・臨床インフラを備えています。このような環境は、学界、研究機関、製薬企業間の効率的な連携を促進し、PDXモデルの効果的な利用と採用を可能にします。
第二に、北米の規制の枠組みは、前臨床および臨床研究におけるPDXモデルを含む革新的技術の統合をサポートしています。厳格な規制基準により、PDXモデルが検証され、医薬品開発プロセスに適用されることが保証されるため、投資家と業界の信頼が高まります。
さらに、アジア太平洋はPDXモデル市場にとって有利な成長の可能性を秘めています。この地域は、強固な医療インフラ、急成長するバイオ医薬品産業、患者数の多さといった利点があり、PDXモデルの利用に理想的な環境を育んでいます。

本レポートのために実施した一次インタビューは以下のように分類されます：
- 回答者別 供給側：63％、需要側：37％
- 役職別 経営者：45％、研究者：30％、管理職：25％
- 国別 北米：40％、ヨーロッパ：25％、アジア太平洋：20％、中南米：10％、中東アフリカ：5％

著名なプレーヤー：
•JSR Corporation (Japan)
•Wuxi Apptec (China)
•The Jackson Laboratory (US)
•Charles River Laboratories International, Inc. (US)
•Taconic Biosciences, Inc. (US)
•Oncodesign Precision Medicine (France)
•Inotiv, Inc. (US)
•Pharmatest Services (Finland)
•Hera BioLabs (US)
•EPO Berlin-Buch GmbH (Germany)
•Xentech (France)
•Urosphere (France)
•Altogen Labs (US)
•Abnova Corporation (US)
•Genesis Biotechnology Group (US)
•Biocytogen Pharmaceuticals Co., Ltd. (China)
•Creative Animodel (US)
•BioDuro-Sundia (US)
•Aragen Life Sciences (India)
•Shanghai LIDE Biotech Co., Ltd. (China)
•Certis Oncology Solutions (US)
•InnoSer (Netherlands)
•IVRS AB (Sweden)
•Beijing IDMO Co. Ltd. (China)
•Shanghai Chempartner Co. Ltd. (China)

調査範囲：
この調査レポートは、患者腫瘍移植/PDXモデル市場の詳細な姿を掲載しています。タイプ、移植方法、腫瘍タイプ、用途、エンドユーザー、地域（北米、ヨーロッパ、アジア太平洋、中南米、中東アフリカ）など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点：
本レポートは、患者腫瘍移植/PDXモデル市場全体およびそのセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー／新規参入者を支援します。また、利害関係者が競合状況をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、動向、機会、および課題に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します：
- 患者腫瘍移植/PDXモデル市場の成長に影響を与える主要な促進要因（個別化医療への需要の高まり、PDX技術の技術的進歩、がん研究への投資の増加）、阻害要因（臨床試験用の動物モデルを廃止するFDAの発表）、機会（生物医学研究におけるCRISPRの出現）、課題（代替動物試験法の開発）の分析しています。
- 製品開発/イノベーション：患者腫瘍移植/PDXモデル市場における今後の技術、研究開発活動、新製品の発売に関する詳細な洞察を掲載しています。
- 市場開発： 有利な市場に関する包括的な情報-本レポートでは、様々な地域における患者腫瘍移植/PDXモデル市場を分析しています。
- 市場の多様化：患者腫瘍移植/PDXモデル市場における新製品、未開拓地域、最近の開発、投資に関する詳細な情報を提供します。
- 競合評価：患者腫瘍移植/PDXモデル市場戦略におけるJSR Corporation (Japan), The Jackson Laboratory (US), and Charles River Laboratories International, Inc. (US)などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価しています。また、本レポートは、関係者が患者腫瘍移植/PDXモデル市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

1.イントロダクション
2.調査方法
3.エグゼクティブサマリー
4.プレミアムインサイト
5.市場概要
6.患者腫瘍移植/PDXモデルの市場分析：移植方法別
7.患者腫瘍移植/PDXモデルの市場分析：種類別
8.患者腫瘍移植/PDXモデルの市場分析：用途別
9.患者腫瘍移植/PDXモデルの市場分析：エンドユーザー別
10.患者腫瘍移植/PDXモデルの市場分析：腫瘍種類別
11.患者腫瘍移植/PDXモデルの市場分析：地域別
12.競争状況
13.企業情報
14.付録

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 INCLUSIONS AND EXCLUSIONS 37
1.4 STUDY SCOPE 38
1.4.1 MARKETS COVERED 38
1.4.2 YEARS CONSIDERED 39
1.4.3 CURRENCY CONSIDERED 39
1.5 LIMITATIONS 39
1.6 STAKEHOLDERS 39
1.7 SUMMARY OF CHANGES 40
1.8 RECESSION IMPACT 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 1 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY DATA 42
FIGURE 2 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: BREAKDOWN OF PRIMARIES 43
2.2 MARKET ESTIMATION METHODOLOGY 43
FIGURE 3 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2023 44
FIGURE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SIZE, 2023 (USD MILLION) 45
FIGURE 5 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: FINAL CAGR PROJECTIONS, 2023−2028 45
FIGURE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46
2.3 DATA TRIANGULATION METHODOLOGY 47
FIGURE 7 DATA TRIANGULATION 47
2.4 INDUSTRY INSIGHTS 48
2.5 RESEARCH ASSUMPTIONS 48
2.6 RECESSION IMPACT 49
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (%) 49
TABLE 2 US HEALTHCARE EXPENDITURE, 2019–2022 (USD MILLION) 49
TABLE 3 US HEALTHCARE EXPENDITURE, 2023–2027 (USD MILLION) 49
 
3 EXECUTIVE SUMMARY 51
FIGURE 8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2023 VS. 2028 (USD MILLION) 52
FIGURE 10 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2023 VS. 2028 (USD MILLION) 52
FIGURE 11 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION 53
4 PREMIUM INSIGHTS 54
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET 54
FIGURE 12 RISING INVESTMENTS IN CANCER RESEARCH AND ADVANCEMENTS IN PDX TECHNOLOGY 54
4.2 NORTH AMERICAN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER AND COUNTRY (2023) 55
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT AND US TO ACCOUNT FOR LARGEST SHARES OF NORTH AMERICAN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET IN 2023 55
4.3 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION 55
FIGURE 14 PRECLINICAL DRUG DEVELOPMENT SEGMENT TO HOLD LARGEST MARKET SHARE IN 2028 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 15 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
TABLE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: IMPACT ANALYSIS 57
5.2.1 DRIVERS 57
5.2.1.1 Growing demand for personalized medicine 57
5.2.1.2 Technological advancements in patient-derived xenograft (PDX) models 58
5.2.1.3 Rising investments in cancer research 58
5.2.2 RESTRAINTS 59
5.2.2.1 Discontinuation of animal models for clinical trials by FDA 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Emergence of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) in biomedical research 59
5.2.4 CHALLENGES 60
5.2.4.1 Development of alternative animal testing methods 60
5.3 TECHNOLOGY ANALYSIS 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 61
FIGURE 16 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET 61
5.5 SUPPLY CHAIN ANALYSIS 62
FIGURE 17 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: SUPPLY CHAIN ANALYSIS 63
TABLE 5 COMPANIES AND THEIR ROLE IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL SUPPLY CHAIN 63
5.6 VALUE CHAIN ANALYSIS 64
FIGURE 18 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: VALUE CHAIN ANALYSIS 65
5.7 ECOSYSTEM ANALYSIS 66
FIGURE 19 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: ECOSYSTEM ANALYSIS 66
5.8 PORTER’S FIVE FORCES ANALYSIS 66
TABLE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS 66
5.8.1 INTENSITY OF COMPETITIVE RIVALRY 66
5.8.2 BARGAINING POWER OF SUPPLIERS 67
5.8.3 BARGAINING POWER OF BUYERS 67
5.8.4 THREAT OF SUBSTITUTES 67
5.8.5 THREAT OF NEW ENTRANTS 67
5.9 REGULATORY ANALYSIS 68
5.9.1 NORTH AMERICA 68
5.9.2 EUROPE 69
5.9.3 ASIA PACIFIC 70
5.9.3.1 China 70
5.9.3.2 Japan 70
5.9.3.3 India 71
5.9.3.4 Australia 72
5.9.4 LATIN AMERICA 72
5.9.5 MIDDLE EAST & AFRICA 72
5.10 PRICING ANALYSIS 73
5.10.1 AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE 73
TABLE 7 AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE (USD) 73
5.10.2 AVERAGE SELLING PRICE (ASP) TREND 73
5.11 PATENT ANALYSIS 74
FIGURE 20 GRANTED PATENTS FOR PDX MODELS, 2011–2023 74
5.12 KEY CONFERENCES AND EVENTS IN 2023 74
TABLE 8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: KEY CONFERENCES AND EVENTS 74
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 75
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 75
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 75
5.13.2 BUYING CRITERIA 75
FIGURE 22 KEY BUYING CRITERIA FOR THREE KEY END USERS 75
6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD 76
6.1 INTRODUCTION 77
TABLE 9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 77
6.2 SUBCUTANEOUS IMPLANTATION 77
6.2.1 FACILITATES REAL-TIME ASSESSMENT OF TUMOR GROWTH 77
TABLE 10 SUBCUTANEOUS IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 78
TABLE 11 SUBCUTANEOUS IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 12 SUBCUTANEOUS IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 13 SUBCUTANEOUS IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 14 SUBCUTANEOUS IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 15 SUBCUTANEOUS IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
6.3 ORTHOTOPIC IMPLANTATION 80
6.3.1 PROVIDES HIGHLY ACCURATE REPRESENTATION OF TUMOR BEHAVIOR 80
TABLE 16 ORTHOTOPIC IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 81
TABLE 17 ORTHOTOPIC IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 18 ORTHOTOPIC IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 19 ORTHOTOPIC IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 20 ORTHOTOPIC IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 21 ORTHOTOPIC IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
6.4 OTHERS 83
TABLE 22 OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 23 OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 24 OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 25 OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 26 OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 27 OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
7 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE 86
7.1 INTRODUCTION 87
TABLE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 87
7.2 MOUSE MODEL 87
7.2.1 GROWING USE IN CANCER RESEARCH AND DRUG DEVELOPMENT 87
TABLE 29 MOUSE MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 30 MOUSE MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 31 MOUSE MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 32 MOUSE MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 33 MOUSE MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 34 MOUSE MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
7.3 RAT MODEL 90
7.3.1 DEVELOPMENT OF NEW TECHNOLOGIES TO CREATE PDX RAT MODELS AT FASTER RATE 90
TABLE 35 RAT MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 36 RAT MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 37 RAT MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 38 RAT MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 39 RAT MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 40 RAT MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION 94
8.1 INTRODUCTION 95
TABLE 41 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 95
8.2 PRECLINICAL DRUG DEVELOPMENT 95
8.2.1 INCREASED NUMBER OF CLINICAL TRIALS 95
TABLE 42 PRECLINICAL DRUG DEVELOPMENT: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 43 PRECLINICAL DRUG DEVELOPMENT: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 44 PRECLINICAL DRUG DEVELOPMENT: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 45 PRECLINICAL DRUG DEVELOPMENT: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 46 PRECLINICAL DRUG DEVELOPMENT: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 47 PRECLINICAL DRUG DEVELOPMENT: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
8.3 BIOMARKER ANALYSIS 98
8.3.1 GROWING DEMAND FOR BIOMARKER-BASED PERSONALIZED CANCER THERAPY 98
TABLE 48 BIOMARKER ANALYSIS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 49 BIOMARKER ANALYSIS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 50 BIOMARKER ANALYSIS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 51 BIOMARKER ANALYSIS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 52 BIOMARKER ANALYSIS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 53 BIOMARKER ANALYSIS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
8.4 TRANSLATIONAL RESEARCH 101
8.4.1 BOOMING PERSONALIZED MEDICINE MARKET 101
TABLE 54 TRANSLATIONAL RESEARCH: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 55 TRANSLATIONAL RESEARCH: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 56 TRANSLATIONAL RESEARCH: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 57 TRANSLATIONAL RESEARCH: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 58 TRANSLATIONAL RESEARCH: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 59 TRANSLATIONAL RESEARCH: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
8.5 BIOBANKS 103
8.5.1 RISING DRUG DISCOVERY AND DEVELOPMENT PROJECTS 103
TABLE 60 BIOBANKS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 61 BIOBANKS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 62 BIOBANKS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 63 BIOBANKS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 64 BIOBANKS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 65 BIOBANKS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER 106
9.1 INTRODUCTION 107
TABLE 66 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 107
9.2.1 ADVANCEMENTS IN TUMOR MICROENVIRONMENT RESEARCH 107
TABLE 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 68 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 69 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, 2021–2028 (USD MILLION) 109
TABLE 70 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 71 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
9.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) 110
9.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY SERVICES 110
TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 74 CONTRACT RESEARCH ORGANIZATIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 75 CONTRACT RESEARCH ORGANIZATIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 76 CONTRACT RESEARCH ORGANIZATIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 77 CONTRACT RESEARCH ORGANIZATIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 78 CONTRACT RESEARCH ORGANIZATIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
9.4 ACADEMIC & RESEARCH INSTITUTIONS 113
9.4.1 RISING R&D INVESTMENTS IN LIFE SCIENCES 113
TABLE 79 ACADEMIC & RESEARCH INSTITUTIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 80 ACADEMIC & RESEARCH INSTITUTIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 81 ACADEMIC & RESEARCH INSTITUTIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 82 ACADEMIC & RESEARCH INSTITUTIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 83 ACADEMIC & RESEARCH INSTITUTIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 84 ACADEMIC & RESEARCH INSTITUTIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
10 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE 116
10.1 INTRODUCTION 117
TABLE 85 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 117
10.2 GASTROINTESTINAL TUMOR MODEL 117
10.2.1 RISING DEMAND FOR EFFECTIVE CANCER THERAPEUTICS 117
TABLE 86 GASTROINTESTINAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 87 GASTROINTESTINAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 88 GASTROINTESTINAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 89 GASTROINTESTINAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 90 GASTROINTESTINAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 91 GASTROINTESTINAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
10.3 GYNECOLOGICAL TUMOR MODEL 120
10.3.1 HIGH INCIDENCE OF TARGET CANCERS 120
TABLE 92 GYNECOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 93 GYNECOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 94 GYNECOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 95 GYNECOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 96 GYNECOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 97 GYNECOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
10.4 RESPIRATORY TUMOR MODEL 123
10.4.1 INCREASING PREVALENCE OF LUNG CANCER 123
TABLE 98 RESPIRATORY TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 99 RESPIRATORY TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 100 RESPIRATORY TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 101 RESPIRATORY TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 102 RESPIRATORY TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 103 RESPIRATORY TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
10.5 UROLOGICAL TUMOR MODEL 126
10.5.1 INCREASING FOCUS OF COMPANIES ON EXPANDING PORTFOLIO OF UROLOGICAL TUMOR MODELS 126
TABLE 104 UROLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 105 UROLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 106 UROLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 107 UROLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 108 UROLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 109 UROLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
 
10.6 HEMATOLOGICAL TUMOR MODEL 128
10.6.1 ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND INCREASING DEMAND FOR PERSONALIZED MEDICINE 128
TABLE 110 HEMATOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 111 HEMATOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 112 HEMATOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 113 HEMATOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 114 HEMATOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 115 HEMATOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
10.7 OTHERS 131
TABLE 116 OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 132
TABLE 117 OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 118 OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 119 OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 120 OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 121 OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133

11 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION 134
11.1 INTRODUCTION 135
TABLE 122 PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 135
11.2 NORTH AMERICA 136
FIGURE 23 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SNAPSHOT 136
TABLE 123 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 124 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 125 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 137
TABLE 126 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 138
TABLE 127 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
TABLE 128 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 139
11.2.1 US 139
11.2.1.1 Growing federal research and development efforts to drive market 139
TABLE 129 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 130 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 140
TABLE 131 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 140
TABLE 132 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
TABLE 133 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 141
11.2.2 CANADA 141
11.2.2.1 Government-led investments in stem cell research to drive market 141
TABLE 134 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 135 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 142
TABLE 136 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 143
TABLE 137 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143
TABLE 138 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 144
11.2.3 NORTH AMERICA: IMPACT OF RECESSION 144
11.3 EUROPE 145
TABLE 139 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 140 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 141 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 146
TABLE 142 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 146
TABLE 143 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 144 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 147
11.3.1 GERMANY 147
11.3.1.1 Increasing investments in biotechnology industry to boost market growth 147
TABLE 145 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 146 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 148
TABLE 147 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 148
TABLE 148 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 149
TABLE 149 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 149
11.3.2 FRANCE 149
11.3.2.1 Increasing government funding for cancer research to support market growth 149
TABLE 150 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 151 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 150
TABLE 152 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 150
TABLE 153 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 151
TABLE 154 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 151
11.3.3 UK 151
11.3.3.1 Rising focus on innovating oncology therapeutics to drive market 151
TABLE 155 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 156 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 152
TABLE 157 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 152
TABLE 158 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 153
TABLE 159 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 153
11.3.4 ITALY 153
11.3.4.1 Growing biotechnology and pharmaceutical industries to drive market 153
TABLE 160 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 161 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 154
TABLE 162 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 154
TABLE 163 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 164 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 155
 
11.3.5 SPAIN 155
11.3.5.1 Increasing investments in clinical trials to promote market growth 155
TABLE 165 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 166 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 156
TABLE 167 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 156
TABLE 168 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 169 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 157
11.3.6 REST OF EUROPE 157
TABLE 170 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 171 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 158
TABLE 172 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 158
TABLE 173 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159
TABLE 174 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 159
11.3.7 EUROPE: IMPACT OF RECESSION 159
11.4 ASIA PACIFIC 160
FIGURE 24 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SNAPSHOT 160
TABLE 175 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 176 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 177 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 161
TABLE 178 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 162
TABLE 179 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 162
TABLE 180 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 163
11.4.1 CHINA 163
11.4.1.1 Government-led fundings for clinical trials in oncology to drive market 163
TABLE 181 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 182 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 164
TABLE 183 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 164
TABLE 184 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165
TABLE 185 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 165
11.4.2 JAPAN 165
11.4.2.1 Advancements in mice model technologies to drive market 165
TABLE 186 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 187 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 166
TABLE 188 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 167
TABLE 189 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 167
TABLE 190 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 168
11.4.3 INDIA 168
11.4.3.1 Favorable government policies for drug development to fuel demand 168
TABLE 191 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 192 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 169
TABLE 193 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 169
TABLE 194 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170
TABLE 195 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 170
11.4.4 SOUTH KOREA 170
11.4.4.1 Rising investments in preclinical drug development to drive demand 170
TABLE 196 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 197 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 171
TABLE 198 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 171
TABLE 199 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 172
TABLE 200 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 172
11.4.5 AUSTRALIA 172
11.4.5.1 Increased funding in clinical trials from research institutions to drive market 172
TABLE 201 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 202 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 173
TABLE 203 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 173
TABLE 204 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174
TABLE 205 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 174
11.4.6 REST OF ASIA PACIFIC 174
TABLE 206 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 207 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 175
TABLE 208 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 175
TABLE 209 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 176
TABLE 210 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 176
11.4.7 ASIA PACIFIC: IMPACT OF RECESSION 176
11.5 LATIN AMERICA 177
TABLE 211 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 212 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 213 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 178
TABLE 214 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 178
TABLE 215 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 179
TABLE 216 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 179
11.5.1 BRAZIL 179
11.5.1.1 Growing need for advanced cancer research and therapeutic development to drive market 179
TABLE 217 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 218 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 180
TABLE 219 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 180
TABLE 220 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181
TABLE 221 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 181
11.5.2 REST OF LATIN AMERICA 181
TABLE 222 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 223 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 182
TABLE 224 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 182
TABLE 225 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 183
TABLE 226 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 183
11.5.3 LATIN AMERICA: IMPACT OF RECESSION 183
11.6 MIDDLE EAST & AFRICA 184
TABLE 227 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 228 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 229 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 185
TABLE 230 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 185
TABLE 231 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 186
TABLE 232 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 186
11.6.1 MIDDLE EAST 186
11.6.1.1 Growing use to probe treatment strategies aligned with individual patient profiles to drive market 186
TABLE 233 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 234 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 187
TABLE 235 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 188
TABLE 236 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 188
TABLE 237 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 189
11.6.2 AFRICA 189
11.6.2.1 Rising incidence of cancer and expanding research infrastructure to drive market 189
TABLE 238 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 239 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION) 190
TABLE 240 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION) 190
TABLE 241 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191
TABLE 242 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 191
11.6.3 MIDDLE EAST & AFRICA: IMPACT OF RECESSION 191
 
12 COMPETITIVE LANDSCAPE 192
12.1 OVERVIEW 192
12.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS 192
FIGURE 25 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: KEY STRATEGIES ADOPTED BY MAJOR PLAYERS 193
12.3 REVENUE SHARE ANALYSIS OF TOP FOUR PLAYERS, 2022 193
FIGURE 26 REVENUE SHARE ANALYSIS FOR TOP FOUR COMPANIES, 2022 194
12.4 MARKET SHARE ANALYSIS OF TOP FOUR PLAYERS, 2020–2022 194
FIGURE 27 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SHARE ANALYSIS OF TOP FOUR PLAYERS, 2020–2022 195
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 196
12.5.1 STARS 196
12.5.2 EMERGING LEADERS 196
12.5.3 PERVASIVE PLAYERS 196
12.5.4 PARTICIPANTS 196
FIGURE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 197
12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMALL AND MEDIUM-SIZED ENTERPRISES (SMES), 2022 198
12.6.1 PROGRESSIVE COMPANIES 198
12.6.2 STARTING BLOCKS 198
12.6.3 RESPONSIVE COMPANIES 198
12.6.4 DYNAMIC COMPANIES 198
FIGURE 29 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022 199
12.7 COMPETITIVE BENCHMARKING 200
12.7.1 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES 200
TABLE 243 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES 200
12.7.2 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 201
TABLE 244 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 201
12.8 COMPETITIVE SCENARIOS AND TRENDS 202
12.8.1 DEALS 202
TABLE 245 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: DEALS, 2021–2023 202
12.8.2 OTHERS 203
TABLE 246 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: OTHERS, 2021–2023 203
 
13 COMPANY PROFILES 204
13.1 KEY PLAYERS 204
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 JSR CORPORATION 204
TABLE 247 JSR CORPORATION: COMPANY OVERVIEW 204
FIGURE 30 JSR CORPORATION: COMPANY SNAPSHOT 205
13.1.2 WUXI APPTEC 208
TABLE 248 WUXI APPTEC: COMPANY OVERVIEW 208
FIGURE 31 WUXI APPTEC: COMPANY SNAPSHOT 209
13.1.3 THE JACKSON LABORATORY 211
TABLE 249 THE JACKSON LABORATORY: COMPANY OVERVIEW 211
FIGURE 32 THE JACKSON LABORATORY: COMPANY SNAPSHOT 211
13.1.4 CHARLES RIVER LABORATORIES 215
TABLE 250 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 215
FIGURE 33 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 216
13.1.5 TACONIC BIOSCIENCES, INC. 220
TABLE 251 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW 220
13.1.6 ONCODESIGN PRECISION MEDICINE 222
TABLE 252 ONCODESIGN PRECISION MEDICINE: COMPANY OVERVIEW 222
FIGURE 34 ONCODESIGN PRECISION MEDICINE: COMPANY SNAPSHOT 222
13.1.7 INOTIV, INC. 224
TABLE 253 INOTIV, INC.: COMPANY OVERVIEW 224
FIGURE 35 INOTIV, INC.: COMPANY SNAPSHOT 225
13.1.8 PHARMATEST SERVICES 227
TABLE 254 PHARMATEST SERVICES: COMPANY OVERVIEW 227
13.1.9 HERA BIOLABS 228
TABLE 255 HERA BIOLABS: COMPANY OVERVIEW 228
13.1.10 EPO BERLIN-BUCH GMBH 230
TABLE 256 EPO BERLIN-BUCH GMBH: COMPANY OVERVIEW 230
13.1.11 XENTECH 231
TABLE 257 XENTECH: COMPANY OVERVIEW 231
13.1.12 UROSPHERE 233
TABLE 258 UROSPHERE: COMPANY OVERVIEW 233
13.1.13 ALTOGEN LABS 234
TABLE 259 ALTOGEN LABS: COMPANY OVERVIEW 234
13.1.14 ABNOVA CORPORATION 235
TABLE 260 ABNOVA CORPORATION: COMPANY OVERVIEW 235
13.1.15 GENESIS BIOTECHNOLOGY GROUP 236
TABLE 261 GENESIS BIOTECHNOLOGY GROUP: COMPANY OVERVIEW 236
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 237
13.2.1 BIOCYTOGEN PHARMACEUTICALS CO., LTD. 237
13.2.2 CREATIVE ANIMODEL 237
13.2.3 BIODURO-SUNDIA INC. 238
13.2.4 ARAGEN LIFE SCIENCES 238
13.2.5 SHANGHAI LIDE BIOTECH CO., LTD. 239
13.2.6 CERTIS ONCOLOGY SOLUTIONS 239
13.2.7 INNOSER 240
13.2.8 IVRS AB 240
13.2.9 BEIJING IDMO CO. LTD. 240
13.2.10 SHANGHAI CHEM PARTNER CO. LTD. 241
14 APPENDIX 242
14.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 245
14.2 CUSTOMIZATION OPTIONS 247
14.3 RELATED REPORTS 247
14.4 AUTHOR DETAILS 248

★調査レポート[世界の患者腫瘍移植/PDXモデル市場（～2028年）：種類別（マウス、ラット）、移植方法別（皮下、同所）、腫瘍種類別（呼吸器、血液）、用途別（医薬品開発、バイオバンク）、エンドユーザー別（製薬、バイオテクノロジー、CRO）] (コード：BT5576-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の患者腫瘍移植/PDXモデル市場（～2028年）：種類別（マウス、ラット）、移植方法別（皮下、同所）、腫瘍種類別（呼吸器、血液）、用途別（医薬品開発、バイオバンク）、エンドユーザー別（製薬、バイオテクノロジー、CRO）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の医薬品受託製造市場（～2028年）：サービス別（医薬品（原薬、FDF-錠剤、カプセル、注射剤））、生物学的製剤（原薬、FDF）、医薬品開発）、エンドユーザー別（大手製薬会社、中小製薬会社、ジェネリック医薬品）
  • 世界のハイスループットスクリーニング市場（～2028年）：製品別（機器、消耗品、サービス）、技術別（セルベースアッセイ、ラボオンチップ、ラベルフリー）、用途別（創薬、生命科学研究）、エンドユーザー別（製薬、バイオテクノロジー、CRO）
  • 世界の人工多能性幹細胞市場2023-2030：由来細胞種類別（肝細胞、線維芽細胞）、用途別（医薬品開発、毒性研究）、エンドユーザー別、地域別
  • 世界の解剖病理学市場2023-2030：製品・サービス別、用途別（疾病診断、創薬・医薬品開発）、エンドユーザー別、地域別
  • 世界の初代細胞市場（～2028年）：種類別（造血、皮膚、肝細胞、消化管、肺、腎、心臓、筋骨格）、由来別（ヒト由来初代細胞、動物由来初代細胞）、エンドユーザー別（製薬、バイオテクノロジー、CRO、学術）、地域別
  • 世界のヒト化マウス＆ラットモデル市場（～2028年）：種類別（遺伝子モデル、細胞ベースモデル（CD34、BLT、PMC）、ラットモデル）、用途別（腫瘍学、免疫学、神経科学、毒物学、感染症）、エンドユーザー別（製薬、バイオテクノロジー）、地域別
  • 世界の創薬サービス市場（～2028年）：プロセス別（ターゲット選択、H2L）、種類別（化学、生物）、薬剤タイプ別（低分子、生物製剤）、治療領域別（腫瘍、神経、感染症）、エンドユーザー別（製薬、バイオテクノロジー、学術）、地域別
  • 世界のシングルユースバイオリアクター（SUB）市場（～2028年）：製品別（装置、メディアバッグ、ろ過アセンブリ）、種類別（攪拌槽、バブルカラム）、細胞タイプ別（哺乳類、バクテリア、酵母）、分子別（mAbs、ワクチン）、エンドユーザー別（製薬、バイオテクノロジー、CRO、CMO）、地域別
  • 世界のデジタルPCR（dPCR）＆リアルタイムPCR（qPCR）市場（～2028年）：製品別（機器、試薬・消耗品、ソフトウェア・サービス）、用途別（臨床、研究、法医学）、エンドユーザー別（病院、診断研究室、製薬、バイオテクノロジー、CRO）
  • 世界の細胞培養培地市場（～2028年）：種類別（無血清（CHO、BHK、Vero Cell）、幹細胞、既知組成、基本、特殊）、用途別（バイオ医薬品（mAb、ワクチン）、診断学、組織工学）、エンドユーザー別（製薬、バイオテクノロジー）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆